Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$0.58
+0.1%
$0.57
$0.34
$2.70
$49.99M1.78578,919 shs639,676 shs
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
$0.73
-0.2%
$0.70
$0.48
$3.44
$13.18M0.81.11 million shs33,594 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$0.82
-4.5%
$0.64
$0.38
$8.01
$79.10M1.76631,598 shs345,421 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.43
-4.0%
$2.67
$1.38
$26.96
$8.63M0.54169,404 shs1.21 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
+0.10%-3.25%-0.95%+6.82%-80.64%
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
-0.15%-7.72%+27.36%+32.55%-75.03%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-4.55%+1.20%+41.03%+66.42%-89.72%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-4.03%0.00%-49.29%-75.02%-93.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
3.3106 of 5 stars
3.55.00.00.02.61.70.6
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
1.1619 of 5 stars
0.03.00.00.03.31.70.6
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4.4022 of 5 stars
3.15.00.04.71.52.50.6
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.9282 of 5 stars
3.54.00.04.62.93.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
3.00
Buy$4.20623.14% Upside
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
0.00
N/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.20
Hold$8.00880.03% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.334,958.28% Upside

Current Analyst Ratings Breakdown

Latest TRIB, XFOR, IPSC, and VRCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $6.00
5/14/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$6.59M7.59N/AN/A$1.90 per share0.31
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
$61.56M0.21N/AN/A($1.95) per share-0.37
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$7.57M9.97N/AN/A($0.11) per share-7.42
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$31.36M0.26N/AN/A$3.90 per share0.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$126.57M-$0.29N/AN/AN/A-19.10%-10.71%-5.96%8/14/2025 (Estimated)
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
-$31.79M-$2.93N/AN/AN/A-68.48%N/A-32.44%8/13/2025 (Estimated)
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$76.58M-$1.20N/AN/AN/AN/AN/A-145.63%8/13/2025 (Estimated)
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.67N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest TRIB, XFOR, IPSC, and VRCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.38N/AN/AN/AN/AN/A
8/14/2025Q2 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.53N/AN/AN/AN/AN/A
8/13/2025Q1 2025
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
-$0.51N/AN/AN/A$16.00 millionN/A
8/13/2025Q2 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.10N/AN/AN/A$4.37 millionN/A
5/15/2025Q1 2025
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million
5/13/2025Q1 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.14-$0.10+$0.04-$0.10$2.53 million$3.44 million
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/AN/AN/AN/AN/A
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/A
11.70
11.70
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
N/A
1.28
0.68
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/A
1.34
1.26
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
50.20%
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
78.97%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
5.00%
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
8.20%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
54.00%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
17086.16 million81.85 millionOptionable
Trinity Biotech PLC stock logo
TRIB
Trinity Biotech
48018.05 million16.57 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4092.49 million42.55 millionOptionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.65 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Century Therapeutics stock logo

Century Therapeutics NASDAQ:IPSC

$0.58 +0.00 (+0.10%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.59 +0.01 (+2.10%)
As of 07/18/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Trinity Biotech stock logo

Trinity Biotech NASDAQ:TRIB

$0.73 0.00 (-0.15%)
Closing price 07/18/2025 03:57 PM Eastern
Extended Trading
$0.72 -0.01 (-1.37%)
As of 07/18/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$0.82 -0.04 (-4.55%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.81 -0.01 (-0.77%)
As of 07/18/2025 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.43 -0.06 (-4.03%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.42 -0.01 (-0.70%)
As of 07/18/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.